
1642



TRANSMITTAL

**FORM** 

09/765,060

January 17, 2001

PTO/SB/21 (08-00)
Approved for use through 10/31/02. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**Application Number** 

Filing Date

## **First Named Inventor** Baofa YU **Group Art Unit** 1642\_ Karen A. CANELLA **Examiner Name** (to be used for all correspondence after initial filing) tal Number Of Pages In This Submission Attorney Docket No. 494492000100 **ENCLOSURES** (check all that apply) **Assignment Papers** After Allowance Communication to Fee Transmittal Form (for an Application) Group Appeal Communication to Board of Fee Attached Drawing(s) Appeals and Interferences Appeal Communication to Group Amendment / Reply Licensing-related Papers (Appeal Notice, Brief, Reply Brief) Petition Proprietary Information After Final Petition to Convert to a Status Letter Affidavits/declarations Provisional Application Other Enclosure(s) (please identify Power of Attorney, Revocation **Extension of Time Request** Change of Correspondence Address below): Return postcard Terminal Disclaimer Express Abandonment Request Request for Refund Information Disclosure Statement: CD, Number of CD(s) PTO form 1449; and references Certified Copy of Priority Document(s) Remarks Response to Missing Parts/ Incomplete Application Response to Missing Parts 25225 under 37 CFR 1.52 or 1.53 PATENT TRADEMARK OFFICE SIGNATURE OF APPLICANT, ATTORNEY OR AGENT Firm Peng Chen Registration No. 43,543 Individual Name Signature Date October 14, 2002

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on October 14, 2002

hear Im

Rhea Amid

Burden Hours Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

RHEA AMID

OCT 2 1 26L2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

OCT 2 3 2002

**↑** In the application of:

Baofa YU

Serial No.: 09/765,060

Filing Date: JANUARY 17, 2001

COMBINATIONS AND METHODS

FOR TREATING NEOPLASMS

TECH CENTER 1600/2900

Group Art Unit: 1642

Examiner: K.A. CANELLA

RESPONSE/AMENDMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

This paper responds to the Restriction Requirement mailed on September 13, 2002, for which a response is due on October 15, 2002 as October 13 being a Sunday and October 14 being a Federal Holiday. Since this response is filed timely, i.e., by October 15, 2002, no fee is required for filing this Response.

The Restriction Requirement requires the election of a single species from each of the Groups (A) - (P) as listed in the May 30, 2002 Restriction Requirement. In response, Applicant elects the species as follows:

- (A) the haptens recited in claim 38: trinitrophenol (TNP);
- (B) the chelators recited in claim 41: doxorubicin adipic-dihydrazide (ADR-ADH);
- (C) the immune response potentiators recited in claim 44: Bacille Calmette-Guerin (BCG);

sd-110833

- (D) the enzymes recited in claim 45: Vibrio cholera neuraminidase (VCN);
- (E) the coagulation lysing agents recited in claim 48:

proteinase K;

- (F) the oxidizing agents recited in claim 51: hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>);
- (G) the reducing agents recited in claim 52: hematoxylin;
- (H) the protein denaturing agents recited in claim 54:

an alcohol;

- (I) the alcohols recited in claim 55: ethanol;
- (J) the anti-angiogenic agents recited in claims 59 and 60: AGM-1470 (TNP-470);
- (K) the anti-neoplasm agents recited in claim 61: an a

an alkylating agent;

(L) the oncogenes recited in claim 64:

Ha-ras;

- (M) the tumor suppressor genes recited in claim 65: p53;
- (N) the coagulation treatments recited in claim 70: laser coagulation (ILC);
- (O) the neoplasms recited in claim 72:

liver; and

(P) the molecules recited in claim 79:

a radiation sensitizer.

Applicant expressly reserves the right under 35 U.S.C. § 121 to file a divisional application directed to the nonelected subject matter during the pendency of this application, or an application claiming priority from this application.

Applicant requests examination of the elected subject matter on the merits.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this

document to <u>Deposit Account No. 03-1952</u> referencing <u>494492000100</u>. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: October 14, 2002

Respectfully submitted,

Ву: \_\_

Peng Chen Registration No. (43,543)

Morrison & Foerster LLP 3811 Valley Centre Drive Suite 500

San Diego, California 92130-2332

Telephone: (858) 720-5117 Facsimile: (858) 720-5125